Abstract 437P
Background
Capecitabine is an oral antimetabolite chemotherapy apply for various types of cancers. One of the most common adverse events of capecitabine is hands-foot-syndrome (HFS). The incidence of HFS is generally about 50%-60%, while grade 3 toxicity occurs about 10%-20%. Interrupting capecitabine due to adverse events improve symptoms but may decrease efficacy of treatment. Products with aloe-vera component was introduced in many studies and showed efficacy in improvement of skin problems. Aloe vera gel with urea cream combination may increase efficacy in HFS for prevention and treatment.
Methods
The study was a randomized single-blinded phase II study. The screening and randomization began in December 2021 until January 2023. Patients who diagnosed with cancer that appropriated for receiving capecitabine were randomized 1:1 by using the block of four. The treatment group received both aloe vera gel and 10% urea cream, while controlled group received 10% urea cream. The sample size was calculated using 90% power to show a 20% reduction of the incidence of HFS grade 2-3 with aloe vera gel plus urea cream. The significant p-value was p-value <0.05.
Results
There were 61 patients in this study. Patients in both groups had a good compliance. There were 30 patients in aloe vera plus 10% urea cream group and 31 patients in 10% urea cream group. In aloe vera plus 10% urea cream group, there are 86.7% in grade 0-1 HFS and 13.3% in grade 2-3 HFS, while in 10% urea cream group, there are 64.5% in grade 0-1 HFS and 35.5% in grade 2-3 HFS, p-value was 0.045.There are statistically significant lower grade 2-3 of HFS in aloe vera and 10% urea cream combination arm. Table: 437P
Severity of HFS
HFS grade | Treatment | Controlled | p-value |
Grade 0-1 | 26 (86.7%) | 20 (64.5%) | 0.045* |
Grade 2-3 | 4 (13.3%) | 11 (35.5%) |
Conclusions
Combination aloe vera gel to 10% urea cream decrease the incidence of grade 2-3 HFS in cancer patients being treated with capecitabine. No statistical difference in quality of life according to DLQI between two groups.
Clinical trial identification
TCTR20230411005.
Editorial acknowledgement
Legal entity responsible for the study
Department of internal medicine, Faculty of Medicine, Vajira hospital, Navamindradhiraj University.
Funding
The present study was supported by the Navamindradhiraj University Research Fund. This study was approved by Vajira institutional Review Board (COA 236/2564).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract